Related Experiment Video
Updated: Feb 20, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express
Kenta Furukawa1, Masahiro Tanemura1, Eiji Miyoshi2
1Department of Gastroenterological Surgery, Osaka Police Hospital, Osaka, Japan.
Objectives:
Single-agent immunotherapy is ineffective against poorly immunogenic cancers, including pancreatic ductal adenocarcinoma (PDAC). The aims of this study were to demonstrate the feasibility of production of novel autologous tumor lysate vaccines from resected PDAC tumors, and verify vaccine safety and efficacy.
Methods:
Fresh surgically resected tumors obtained from human patients were processed to enzymatically synthesize α-gal epitopes on the carbohydrate chains of membrane glycoproteins. Processed membranes were analyzed for the expression of α-gal epitopes and the binding of anti-Gal, and vaccine efficacy was assessed in vitro and in vivo.
Results:
Effective synthesis of α-gal epitopes was demonstrated after processing of PDAC tumor lysates from 10 different patients, and tumor lysates readily bound an anti-Gal monoclonal antibody. α-gal(+) PDAC tumor lysate vaccines elicited strong antibody production against multiple tumor-associated antigens and activated multiple tumor-specific T cells. The lysate vaccines stimulated a robust immune response in animal models, resulting in tumor suppression and a significant improvement in survival without any adverse events.
Conclusions:
Our data suggest that α-gal(+) PDAC tumor lysate vaccination may be a practical and effective new immunotherapeutic approach for treating pancreatic cancer.
Insights
This study shows that autologous tumor lysate vaccines, engineered with α-gal epitopes, are a safe and effective new immunotherapy for pancreatic cancer (PDAC). These vaccines stimulate a strong immune response, suppress tumors, and improve survival in models.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Single-agent immunotherapy shows limited efficacy in poorly immunogenic cancers like pancreatic ductal adenocarcinoma (PDAC).
- Novel therapeutic strategies are needed to overcome the challenges of treating pancreatic cancer.
Purpose of the Study:
- To establish the feasibility of producing autologous tumor lysate vaccines from resected PDAC tumors.
- To evaluate the safety and efficacy of these novel vaccines.
Main Methods:
- PDAC tumors were processed to enzymatically synthesize α-gal epitopes on membrane glycoproteins.
- Vaccine production involved analyzing α-gal epitope expression and anti-Gal binding.
- In vitro and in vivo studies assessed vaccine efficacy.
Main Results:
- Successful synthesis of α-gal epitopes was confirmed in lysates from 10 PDAC patients.
- α-gal(+) PDAC tumor lysate vaccines induced robust antibody and T cell responses against tumor antigens.
- Vaccines demonstrated tumor suppression and significantly improved survival in animal models without adverse events.
Conclusions:
- Autologous α-gal(+) PDAC tumor lysate vaccination represents a feasible and promising immunotherapeutic approach.
- This strategy may offer a new treatment option for pancreatic cancer patients.
- Further clinical investigation is warranted to validate these findings.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...